Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;33(4):e13770.
doi: 10.1111/pai.13770.

Remission of eczema and recovery of Th1 polarization following treatment with Dupilumab in STAT3 hyper IgE syndrome

Caterina Matucci-Cerinic  1   2 , Gianmaria Viglizzo  3 , Carlotta Pastorino  3 , Anna Corcione  2 , Ignazia Prigione  2 , Paola Bocca  2 , Marta Bustaffa  1   2 , Massimiliano Cecconi  4 , Marco Gattorno  2   5 , Stefano Volpi  1   2
Affiliations

Remission of eczema and recovery of Th1 polarization following treatment with Dupilumab in STAT3 hyper IgE syndrome

Caterina Matucci-Cerinic et al. Pediatr Allergy Immunol. 2022 Apr.
No abstract available

Keywords: Dupilumab; HIES; STAT3; Th1; Th2; hyper IgE syndrome; immunodeficiency; job syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
(A) Cutaneous lesions before (upper pictures) and after (lower pictures) treatment with dupilumab; (B) Sanger sequencing; (C) Modification of SCORAD, DLQI, IgE, eosinophils, IL‐4 and CXCL1 before and after 12 months of treatment; (D) Modification of Th1, Th2 and Th17 lymphocytes before and after 12 months of treatment
FIGURE 2
FIGURE 2
Behaviour of IL‐13, IL‐10, CXCL9, TNFα, IL‐6 and IL‐1β before and after 1, 5, 12 and 13 months of dupilumab. Cytokine/chemokine profiling: The BD CBA assays for human soluble protein (BD Bioscience 558264) was used to assess plasma cytokine/chemokines according to the manufacturer's protocols. Data were analysed with the FCAP Array software. Flow cytometry evaluation of lymphocytes was performed on 50 µl of whole blood. Cells were stained with membrane markers CD3, CD4 and CD8, fixed and permeabilized (Cytofix/Cytoperm [BD]); T lymphocyte polarization was defined in CD3+CD4+CD8− cells by intracellular expression of IFN‐g for Th1, IL‐4 for TH‐2 and IL‐17 for Th17
See this image and copyright information in PMC

References

    1. Holland SM, DeLeo FR, Elloumi HZ, et al. STAT3 mutations in the hyper‐IgE syndrome. N Engl J Med. 2007;357(16):1608‐1619. - PubMed
    1. Milner JD, Brenchley JM, Laurence A, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper‐IgE syndrome. Nature. 2008;452(7188):773‐776. - PMC - PubMed
    1. Sogkas G, Hirsch S, Jablonka A, Witte T, Schmidt RE, Atschekzei F. Dupilumab to treat severe atopic dermatitis in autosomal dominant hyper‐IgE syndrome. Clin Immunol. 2020;215:108452. - PubMed
    1. Dixit C, Thatayatikom A, Pappa H, Knutsen AP. Treatment of severe atopic dermatitis and eosinophilic esophagitis with dupilumab in a 14‐year‐old boy with autosomal dominant hyper‐IgE syndrome. J Allergy Clin Immunol Pract. 2021;9(11):4167‐4169. - PubMed
    1. Su CJ, Tseng HC. Treatment efficacy of dupilumab in a hyper‐immunoglobulin E syndrome patient with severe atopic dermatitis. JAAD Case Rep. 2021;9(11):60‐62. - PMC - PubMed

MeSH terms